CMPX Stock Analysis
CM
Uncovered
Compass Therapeutics Inc. is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.235
Dividend yield
—
Shares outstanding
126.51 B
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2020-11-13. The firm is focused on developing antibody-based therapeutics to treat multiple human diseases. Its pipeline of product candidates targets multiple critical biological pathways required for an anti-tumor response, which include modulation of the microvasculature via angiogenesis-targeted agents. Its clinical-stage product candidates include CTX-009 and CTX-471. CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). Its monoclonal antibody product candidate, CTX-471, is a fully human, IgG4 monoclonal antibody that is an agonist of CD137, a key costimulatory receptor on immune cells. Its third program, CTX-8371, is a bispecific antibody that binds to both PD-1 and PD-L1, the target checkpoint inhibitor antibodies. The company is also developing a portfolio of bispecific and monoclonal antibody product candidates.